Date: 2014-05-30
Type of information: Distribution agreement
Compound: Cationorm®
Company: Nicox (France) Eupharmed (Italy) Santen SAS (France)
Therapeutic area: Ophtalmological diseases
Type agreement: distribution
Action mechanism: Cationorm® is an iemulsion to treat dry eye symptoms (classed as a medical device) with the Novasorb® technology. It is a cationic oil-in-water emulsion, which protects, moisturizes and lubricates the ocular surface to ensure a sustained relief and reduce the dry eyes symptoms such as stinging and sandy gritty. Cationorm® contains small positively charged droplets with an oily core that are electrostatically attracted by the negatively charged ocular surface. It spreads on the ocular surface directly after application and supports all three layers of the tear film due to its unique composition.
Disease: dry eye symptoms
Details: * On May 30, 2014, Nicox announced that its wholly-owned Italian subsidiary Eupharmed has entered into an exclusive agreement with Santen SAS, enabling Eupharmed to continue to distribute Cationorm® in Italy. Cationorm® has been distributed by Eupharmed in Italy since 2010 under a previous agreement expiring on July 29, 2014. Under the terms of the agreement announced , Eupharmed will continue to have the rights to promote and sell Cationorm® in Italy on an exclusive basis until December 31, 2016.
Financial terms: As agreed at the time of the Eupharmed acquisition in December 2013, Nicox will make an additional earn-out payment to Fin Posillipo SPA, Eupharmed’s former shareholder, linked to the extension of the distribution agreement. The earn-out payment will be made in the form of 821,996 newly issued Nicox shares, which will be subject to certain lock-up provisions.
Latest news:
